Connor Iapoce

12-month adherence to GLP1-RA or SGLT2i therapies was highest among individuals with T2D and/or heart failure with a low prescription co-payment.

Results from the phase 3 CHAMP trial may support low-dose atropine as a pharmacological treatment option for myopia progression in children.

An analysis in Denmark observed increased adherence and persistence in latanoprost users who switched between different latanoprost formulations.

Announced in a release by Daiichi Sankyo, Inc. and American Regent, Inc., the therapy is now the first and only intravenous iron replacement therapy indicated for adult patients with heart failure who have iron deficiency.

An analysis of the Ontario Health WTIS database suggests the presence of systematic sex-based differences could be affecting the timeliness of ophthalmic surgery for women.

The biggest predictors of retinal sensitivity loss during 2 years of anti-VEGF treatment included RPE atrophy, Type 2 MNV, cystoid intraretinal spaces, and the presence of SRT.

Intravitreal anti-VEGF injections were associated with an increase in the likelihood of systemic adverse events among patients with diabetic retinopathy.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our May 2023 month-in-review features new FDA approvals, the future of artificial intelligence in eye care, and interesting crossover coverage.

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our May 2023 month in review features new FDA approvals, important phase 2 data, and in-depth clinician perspective.

The analysis of adults with Type 2 diabetes found 33.4% showed signs of undetected CVD, as indicated by elevated levels of 2 cardiac biomarkers, compared to only 16.1% of those without diabetes.

An analysis of 2 population-based cohorts suggests coronary artery calcium scores added to traditional risk-based models showed better discrimination than polygenic risk scores for CHD risk prediction.

An analysis of over 300,000 Medicare admissions showed no clinically important differences regarding mortality, readmission, length of stay, and healthcare spending between the two groups.

Clinical trial data suggest overweight and obese patients with atrial fibrillation who lose weight prior to a catheter ablation procedure experience better clinical outcomes.

Differences in Lp(a) level distribution across the diverse US Hispanic or Latino population may have important implications for its use in ASCVD risk assessment.

Results from the analysis suggest participants treated for previously diagnosed obstructive sleep apnea experience a significantly higher risk of having RPD coexistent with AMD.

A posthoc analysis of the EMPEROR-Preserved trial suggested empagliflozin decreased the risk of heart failure hospitalization or cardiovascular death, regardless of background diuretic status.

The findings could provide insight into incorporating both OCTA and artificial intelligence for early detection of DMI and better enhancing the management of diabetic retinopathy.

An analysis of the UK Biobank found menstrual cycles less than 21 days or longer than 35 days were associated with a 19% higher risk of CVD compared with a regular menstrual cycle length.

Phase 2 data suggest the oral small-molecule GLP-1R agonist reduced HbA1c at all dose levels studied and reduced body weight at doses of ≥80 mg twice daily compared with placebo in adults with T2D.

In this episode, Veeral Sheth, MD, sits down with Jay Duker, MD for a discussion on his storied career, fostering relationships with industry, and the current technology being worked on at Eyepoint Pharmaceuticals for retinal disorders.

The analysis indicated a 41.4% decrease in the number of OR visits after the COVID-19 pandemic with a parallel decrease in the number of intravitreal injections, compared to the pre-COVID period.

A new analysis found differences in the gut bacteria seen in adults with obesity, suggesting that changes in the gut microbiota that predispose to adult obesity may begin in early childhood.

More data is needed to determine whether low-dose levodopa use reduces conversion to neovascular AMD.

Modified production of abicipar was linked to a moderately lower incidence and severity of IOI in nAMD eyes compared with Phase 3 results, but further reductions in IOI are required to match the incidence rates of other anti-VEGF therapies.

According to a release from Oculis, the trial met its stage 1 objective of validating the dosing regimen designed to optimize the efficacy potential of OCS-01 with statistical significance.

However, trends in the incidence of eye injuries associated with non-powder guns should be interpreted with caution as COVID-19 may have interfered with epidemiological trends.

The structure of the retinal vasculature may be able to predict the initial treatment response to intravitreal therapy in patients with treatment-naïve nAMD.

Announced by Bausch + Lomb and Novaliq, the prescription eye drop for DED is the first and only drop that directly targets tear evaporation, with approval based on results from 2 pivotal phase 3 trials.

An economic evaluation of the SCORE2 trial indicates aflibercept treatment was unlikely to meet most accepted standards of cost-effectiveness, due to little difference in visual acuity outcomes and a large cost differential compared with bevacizumab.

Cost-effective smartphone-based fundus imaging systems may be effective for the detection of treatment-requiring ROP, and help increase the global capacity for ROP screening.